Pharmacokinetic drug-drug interaction study between raltegravir and atorvastatin 20 mg in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 1, 2015, Pages 44-51

  Blonk, Maren ^a   Van Beek, Michiel ^a   Colbers, Angela ^a   Schouwenberg, Bas ^a   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

atorvastatin; drug drug interaction; HIV; hypercholesterolemia; pharmacokinetics; raltegravir

Indexed keywords

2 HYDROXY ATORVASTATIN; 4 HYDROXY ATORVASTATIN; AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; DRUG METABOLITE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOATING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NONINVASIVE BRAIN STIMULATION; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA; ADOLESCENT; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG INTERACTION; PLASMA; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEPTANOIC ACIDS; HUMANS; LIPIDS; MALE; PLASMA; PYRROLES; PYRROLIDINONES; TIME FACTORS; YOUNG ADULT;

EID: 84928407728     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000544     Document Type: Article

References (41)

1. Nachega JB, Hsu AJ, Uthman OA, et al. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;26 (suppl 1):S39-S53.
2. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205(suppl 3):S355-S361.
3. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37: 613-627.
4. EACS. European AIDS Clinical Society. European Guidelines for Treatment of HIV Infected Adults in Europe. Version 7.2, June 2014. 2014. Available at: http://www.eacsociety.org/Portals/0/140601-EACS%20EN7.02.pdf. Accessed August 6, 2014.
5. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. May 1, 2014. 2014;1-285. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 2, 2014.
6. Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes. 2011;18:144-147.
7. Martinez E, Leyes P, Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS. 2008;3:240-246.
8. Ahmed MH, Al-Atta A, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother. 2012;13:1901-1909.
9. Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52: 387-395.
10. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-764.
11. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471-1479.
12. De Wit S, Delforge M, Necsoi CV, et al. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25:1332-1333.
13. Samineni D, Desai PB, Sallans L, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52:922-931.
14. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578.
15. Burger D, Reiss P, Stroes E. Drug interactions between statins and antiretroviral agents. Curr Opin HIV AIDS. 2008;3:247-251.
16. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815-831.
17. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307-312.
18. Martinez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26:2315-2326.
19. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab Dispos. 2007;35:1657-1663.
20. EMA Isentress. Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000860/WC500037405.pdf.
21. Rizk ML, Houle R, Chan GH, et al. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. Antimicrob Agents Chemother. 2014;58:1294-1301.
22. Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2011;55:879-887.
23. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141-1160.
24. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30:505-512.
25. FDA. Isentress: Prescribing Information. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022145s032,203045s010,205786s001lbl.pdf.
26. FDA. Lipitor: Prescribing Information. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020702s062s063lbl.pdf.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
28. Burger D, Teulen M, Eerland J, et al. The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program. Ther Drug Monit. 2011; 33:239-243.
29. DiFrancesco R, Tooley K, Rosenkranz SL, et al. Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin Pharmacol Ther. 2013;93:479-482.
30. Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Ther. 2002;72:229-237.
31. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. 2001. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf. Accessed August 6, 2014.
32. EMA. Guideline on the Investigation of Bioequivalence. 2010. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf.
33. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581.
34. Narwal R, Akhlaghi F, Asberg A, et al. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Clin Pharmacokinet. 2010;49:693-702.
35. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67:460-464.
36. Siccardi M, D'Avolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit. 2012;34:232-235.
37. Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87:65-73.
38. Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a raltegravir-based antiretroviral regimen. Journal of Microbiology, Immunology and Infection. 2013; pii: S1684-1182(13)00034-0.
39. Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr. 2013;62:525-533.
40. Monteiro P, Perez I, Pich J, et al. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. J Antimicrob Chemother. 2013;68:404-408.
41. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79:532-539.